In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

AHA 2022 A phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of NTLA-2001, a CRISPR/Cas9-based in vivo gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy.

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

CSI Barcelona What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.